| TOP STORY | UCSB Scientists Discover New Direction in Alzheimer’s Research In what they are calling a new direction in the study of Alzheimer’s disease, scientists have made an important finding about what happens to brain cells that are destroyed in Alzheimer’s disease and related dementias. [Press release from the University of California, Santa Barbara discussing online prepublication in The Journal of Biological Chemistry]
|
| INDUSTRY NEWS | $1.1 Million Donation for Pioneering Stem Cell MS Trial Multiple Sclerosis research is to benefit from a $1.1 million donation to further a pioneering bone marrow stem cell trial, which has been shown to have possible benefits for the treatment of the disease. [University of Bristol Press Release] Tocagen’s First-in-Human Clinical Trial of Toca 511 Enrolling Patients with High Grade Glioma Tocagen Inc. announced the company is enrolling patients with recurrent high grade glioma, such as those with glioblastoma multiforme, in its first-in-human clinical trial of Toca 511. [PR Newswire] Neuralstem and Summit Pharmaceuticals Enter Into Exclusive Agency Agreement to License NSI-189 Rights in Japan Neuralstem, Inc. announced that it has signed an exclusive agency licensing agreement with Summit Pharmaceuticals International Corporation, of Tokyo, Japan, a wholly owned subsidiary of Sumitomo Corporation Group. [Neuralstem, Inc. Press Release] Researchers at Nationwide Children’s Hospital Receive New Grant to Study How Pediatric Brain Tumor, Ependymoma, Develops Armed with new grant support, investigators at Nationwide Children’s Hospital plan to examine how a common gene of the nervous system leads to the development of a devastating brain tumor, ependymoma. [Nationwide Children’s Hospital Press Release] |
| EVENTS | NEW Neuroscience 2011 November 12-16, 2011 Washington, DC, United States Visit our events page to see a complete list of events in the neural cell community. |
|
|
|